N-(m-methylbenzyl)acetamide | 55329-66-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(m-methylbenzyl)acetamide
• 英文别名: N-(3-methyl-benzyl)-acetamide；N-(3-Methyl-benzyl)-acetamid；Acetyl-(3-methyl-benzylamin)；Acetyl-m-tolubenzylamin；m-Methyl-N-acetylbenzylamin；3-Methylbenzylamin-acetat；N-[(3-methylphenyl)methyl]acetamide
• CAS: 55329-66-3
• 化学式: C₁₀H₁₃NO
• 分子量: 163.219
• InChiKey: YKIRGYAJMYYVQT-UHFFFAOYSA-N

物化性质

• 沸点：
  160-165 °C(Press: 1 Torr)
• 密度：
  1.013±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(m-methylbenzyl)acetamide 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 氯仿 为溶剂， 反应 18.0h， 以79%的产率得到3-甲基苯甲醛
  参考文献：
  名称：

  Direct Oxidation of N‐Benzylamides to Aldehydes or Ketones by N‐Bromosuccinimide

  摘要：

  A simple and efficient approach for the one-pot transformation of N-benzylamides to aldehydes or ketones under mild conditions was reported. All the 20 substrates gave moderate to excellent oxidative yields under the optimized conditions. Our study may provide a new approach for the one-pot synthesis of aldehydes or ketones from the corresponding amides.

  DOI：

  10.1080/00397910801929697
• 作为产物：
  描述：

  3-甲基苄醇 生成 N-(m-methylbenzyl)acetamide
  参考文献：
  名称：

  Shine Henry J., Yueh Wang, J. Org. Chem, 59 (1994) N 13, S 3553-3559

  摘要：

  DOI：

文献信息

• NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS
  申请人：Pellechia Maurizio

  公开号：US20100267781A1

  公开（公告）日：2010-10-21

  Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: wherein each R is independently H, C(O)X, C(O)NHX, NH(CO)X, SO 2 NHX, or NHSO 2 X, wherein X is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, heterocycle, or substituted heterocycle. Compounds of group A may be used for treating various diseases or disorders, such as cancer.

  使用阿波戈朴和其衍生物治疗炎症的方法被披露。此外，还描述了一组具有结构A的化合物，或其药学上可接受的盐、水合物、N-氧化物或溶剂化合物： 其中每个R独立地是H、C(O)X、C(O)NHX、NH(CO)X、SO2NHX或NHSO2X，其中X是氢、烷基、取代烷基、芳基、取代芳基、烷基芳基、取代烷基芳基、杂环或取代杂环。A组化合物可用于治疗各种疾病或疾病，如癌症。
• [EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS
  申请人：FOGHORN THERAPEUTICS INC

  公开号：WO2019152437A1

  公开（公告）日：2019-08-08

  The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

  本公开涉及用于治疗BAF复合物相关疾病的化合物。
• Aerobic Oxidation of <i>N</i>-Alkylamides Catalyzed by <i>N</i>-Hydroxyphthalimide under Mild Conditions. Polar and Enthalpic Effects
  作者：Francesco Minisci、Carlo Punta、Francesco Recupero、Francesca Fontana、Gian Franco Pedulli

  DOI：10.1021/jo016398e

  日期：2002.4.1

  O(2), catalyzed by N-hydroxyphthalimide (NHPI) and Co(II) salt, leads under mild conditions to carbonyl derivatives (aldehydes, ketones, carboxylic acids, imides) whose distribution depends on the nature of the alkyl group and on the reaction conditions. Primary N-benzylamides lead to imides and aromatic aldehydes at room temperature without any appreciable amount of carboxylic acids, while under the

  由N-羟基邻苯二甲酰亚胺（NHPI）和Co（II）盐催化的O（2）对N-烷基酰胺的氧化在温和条件下导致羰基衍生物（醛，酮，羧酸，酰亚胺）的分布取决于性质烷基的取代基和反应条件。N-苄基伯酰胺在室温下可生成酰亚胺和芳族醛，而无需添加任何量的羧酸，而在相同条件下，即使在非常低的转化率下，非苄基衍生物也可生成不含痕量醛的羧酸和酰亚胺。这些结果通过邻苯二甲酰亚胺-N-氧基（PINO）自由基的夺氢来解释，该邻苯二甲酰亚胺-N-氧基（PINO）与苄基衍生物的反应性受极性作用的支配，因此苄酰胺比相应的醛更具反应性。焓效应是，非苄基酰胺占主导地位，使相应的醛比起始酰胺更具反应性。强调了NHPI中OH键的键解离能（BDE）的重要性。
• Simple, High Yield Preparation of<i>N</i>-Benzylacetamides by Lewis Acid-Catalyseed Reaction of Benzyl Chlorides or Benzyl Methyl Ethers with Acetonitrile
  作者：Mesut Kacan、Alexander McKillop

  DOI：10.1080/00397919308018613

  日期：1993.8

  Abstract Reaction of either benzyl chlorides or benzyl methyl ethers with hydrated ferric chloride in acetonitrile results in smooth Ritter reaction and formation of N-benzylacetamides in excellent yield.

  摘要 苄基氯或苄基甲基醚与水合氯化铁在乙腈中的反应会导致平稳的 Ritter 反应并以优异的产率形成 N-苄基乙酰胺。
• SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20150329556A1

  公开（公告）日：2015-11-19

  The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR 1 (R 1 is a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, R 2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X′ is S, O, SO, or CH 2 ), and at least one of ring B and ring C has substituent(s), provided that N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]2 hydroxypropyl}5,6 dimethyl 4 oxo 1,4 dihydrothieno[2,3-d]pyrimidine-2-carboxamide is excluded, or a salt thereof.

  本发明提供了一种新型酰胺衍生物，具有基质金属蛋白酶抑制活性，并且作为药用剂是有用的，该化合物由以下式(I)表示，其中环A是一个可选择取代的含氮杂环，环B是一个可选择取代的单环同核环或可选择取代的单环杂环，Z是N或NR1（R1是氢原子或可选择取代的碳氢基团），是一个单键或双键，R2是氢原子或可选择取代的碳氢基团，X是一个具有1到6个原子的可选择取代的间隔物，环C是（1）一个可选择取代的同核环或（2）一个除了由（II）表示的环之外的可选择取代的杂环（X′是S、O、SO或CH2），并且环B和环C中至少有一个有取代基，但不包括N-(1S,2R)-1-(3,5-二氟苄基)-3-[(3-乙基苄基)氨基]2-羟基丙基}5,6-二甲基-4-氧代-1,4-二氢噻唑并[2,3-d]嘧啶-2-羧酰胺，或其盐。